Multistage Carcinogenesis Models

Author(s):  
Claire D. Sherman ◽  
Christopher J. Portier
Risk Analysis ◽  
2016 ◽  
Vol 37 (7) ◽  
pp. 1375-1387 ◽  
Author(s):  
Andrew F. Brouwer ◽  
Rafael Meza ◽  
Marisa C. Eisenberg

Blood ◽  
2012 ◽  
Vol 119 (19) ◽  
pp. 4363-4371 ◽  
Author(s):  
Tomas Radivoyevitch ◽  
Lynn Hlatky ◽  
Julian Landaw ◽  
Rainer K. Sachs

Abstract Mathematical models of chronic myeloid leukemia (CML) cell population dynamics are being developed to improve CML understanding and treatment. We review such models in light of relevant findings from radiobiology, emphasizing 3 points. First, the CML models almost all assert that the latency time, from CML initiation to diagnosis, is at most ∼ 10 years. Meanwhile, current radiobiologic estimates, based on Japanese atomic bomb survivor data, indicate a substantially higher maximum, suggesting longer-term relapses and extra resistance mutations. Second, different CML models assume different numbers, between 400 and 106, of normal HSCs. Radiobiologic estimates favor values > 106 for the number of normal cells (often assumed to be the HSCs) that are at risk for a CML-initiating BCR-ABL translocation. Moreover, there is some evidence for an HSC dead-band hypothesis, consistent with HSC numbers being very different across different healthy adults. Third, radiobiologists have found that sporadic (background, age-driven) chromosome translocation incidence increases with age during adulthood. BCR-ABL translocation incidence increasing with age would provide a hitherto underanalyzed contribution to observed background adult-onset CML incidence acceleration with age, and would cast some doubt on stage-number inferences from multistage carcinogenesis models in general.


1999 ◽  
Vol 23 (4) ◽  
pp. 273-279 ◽  
Author(s):  
Hiroshi Yamasaki ◽  
Yasufumi Omori ◽  
Maria-Lucia Zaidan-Dagli ◽  
Nikolai Mironov ◽  
Marc Mesnil ◽  
...  

2006 ◽  
Vol 37 (9) ◽  
pp. 1809-1812
Author(s):  
William D. Hazelton ◽  
Stanley B. Curtis ◽  
Suresh H. Moolgavkar

1989 ◽  
Vol 8 (2) ◽  
pp. 241-243
Author(s):  
Seymour J. Garte

Oncogene activation in multistage carcinogenesis is discussed. Results from a number of in vitro studies are cited. An understanding of the mechanisms that suppress activated ras oncogene-induced transformation by protease inhibitors is expected to shed light on the process of multistage carcinogenesis.


2002 ◽  
Vol 22 (3A) ◽  
pp. A43-A49 ◽  
Author(s):  
E Georg Luebeck ◽  
William D Hazelton

2004 ◽  
Vol 2004 (2) ◽  
pp. 93-98 ◽  
Author(s):  
Jamal M. Arif ◽  
Amal A. Al-Hazzani ◽  
Muhammed Kunhi ◽  
Fahad Al-Khodairy

In the past several decades, marine organisms have generously gifted to the pharmaceutical industries numerous naturally bioactive compounds with antiviral, antibacterial, antimalarial, anti-inflammatory, antioxidant, and anticancer potentials. But till date only few anticancer drugs (cytarabine, vidarabine) have been commercially developed from marine compounds while several others are currently in different clinical trials. Majority of these compounds were tested in the tumor xenograft models, however, lack of anticancer potential data in the chemical- and/or oncogene-induced pre-initiation animal carcinogenesis models might have cost some of the marine anticancer compounds an early exit from the clinical trials. This review critically discusses importance of preclinical evaluation, failure of human clinical trials with certain potential anticancer agents, the screening tests used, and choice of biomarkers.


1986 ◽  
Vol 6 (6) ◽  
pp. 1943-1950
Author(s):  
W L Hsiao ◽  
T Wu ◽  
I B Weinstein

Rat embryo fibroblast cell line 6 was transfected with plasmid pT24, which contains the activated human bladder c-Ha-ras oncogene, and the cells were grown continuously in the absence or presence of the tumor promoters 12-O-tetradecanoyl phorbol-13-acetate (TPA) or teleocidin. The presence of TPA or teleocidin led to a 6- to 14-fold increase in the number of morphologically transformed foci. No transformed foci were seen when rat 6 cells were transfected with the normal c-Ha-ras oncogene in the absence or presence of TPA, or in cells simply treated with TPA or teleocidin. Enhancement of pT24-induced foci was seen even when the addition of TPA was delayed until day 16. In transfection studies with the drug resistance genes gpt and neo, TPA and teleocidin did not increase the number of Gpt+ or Neo+ colonies. When rat 6 cells were cotransfected with pT24 and neo genes and grown in the absence or presence of TPA, the presence of TPA did not increase the yield of Neo+ colonies but caused a fivefold increase in the number of Neo+ colonies that displayed a transformed morphology. Southern blot analyses of DNAs obtained from these clones indicated that TPA treatment did not influence the extent of integration of either the pT24 or neo gene. DNA samples from all of the morphologically transformed cells displayed a characteristic 2-kilobase SacI fragment homologous to pT24 DNA and expressed relatively high levels of the corresponding mRNA. Our findings indicate that in this system tumor promoters do not simply enhanced the process of DNA transfection per se. Thus, this model system may be useful for analyzing synergistic interactions between tumor promoters and activated oncogenes during multistage carcinogenesis. It may also serve as a simple screening test for detecting new tumor promoters.


Sign in / Sign up

Export Citation Format

Share Document